MKC1106-MT “Strategies in DNA vaccine for melanoma cancer”
Dec 26, 2020 13:03:59 GMT -5
lennymnkd, boca1girl, and 2 more like this
Post by geomean on Dec 26, 2020 13:03:59 GMT -5
For those old hands who remember Colby and it’s spin out Allecure and the lymph-node injection technology MKC1106 Mannkind transferred out (licensed) to Colby in exchange for future milestone payments and product royalties, here’s a link to a Oct, 2020 article “Strategies in DNA vaccine for melanoma cancer” which reports using the MKC1106-MT as follows:
“The multi‐component active immunotherapy (MKC1106‐MT) is an immunotherapeutic consisting of a recombinant plasmid (pMEL‐TYR) which encodes for MART‐1 and tyrosinase as two melanoma‐associated proteins. This immunotherapy regimen uses different doses of the DNA construct (500 μg, 1,000 μg, and 1,500 μg). The administration of the vaccine was done through IN into the lymph node in the patient with stage IV melanoma. The vaccination resulted in the induction of immune responses and is associated with favorable clinical outcomes in phase I/II trial (NCT00033228).”
From onlinelibrary.wiley.com/doi/full/10.1111/pcmr.12933
This study again raises questions previously raised in threads here about Colby and Allcures which ultimately concluded could only be answered by Management, namely what are the prospects of the MKC1106 technology ever generating milestone payments and royalties.
For some technical history search “Intra-lymph node injection Mannkind” in Google Scholar and for the most current work in the field search “Intra-lymph node injection”. I found the cited article by searching for “MKC1106”. It may by that I’ve merely picked up a NHI classification See ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&version=20.11e&code=C77971&ns=ncit
“The multi‐component active immunotherapy (MKC1106‐MT) is an immunotherapeutic consisting of a recombinant plasmid (pMEL‐TYR) which encodes for MART‐1 and tyrosinase as two melanoma‐associated proteins. This immunotherapy regimen uses different doses of the DNA construct (500 μg, 1,000 μg, and 1,500 μg). The administration of the vaccine was done through IN into the lymph node in the patient with stage IV melanoma. The vaccination resulted in the induction of immune responses and is associated with favorable clinical outcomes in phase I/II trial (NCT00033228).”
From onlinelibrary.wiley.com/doi/full/10.1111/pcmr.12933
This study again raises questions previously raised in threads here about Colby and Allcures which ultimately concluded could only be answered by Management, namely what are the prospects of the MKC1106 technology ever generating milestone payments and royalties.
For some technical history search “Intra-lymph node injection Mannkind” in Google Scholar and for the most current work in the field search “Intra-lymph node injection”. I found the cited article by searching for “MKC1106”. It may by that I’ve merely picked up a NHI classification See ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&version=20.11e&code=C77971&ns=ncit
